Dima suki
University of Texas , USA
Title: Long-Term Survival in Patients with Glioblastoma Multiforme: Frequency and Prognostic Factors
Biography
Biography: Dima suki
Abstract
Glioblastoma multiforme (GBM) is a highly aggressive and rapidly fatal primary brainrntumor. Median patient survival is 12-14 months. Few treated patients survive beyond 5 years.rnVariation in characteristics such as age, performance status, and extent of resection (EOR) canrnextend survival for a few months. However, factors associated with long-term survivals of ≥5 yearsrnare largely unknown, and identifying them may provide insight into GBM and its management. Wernidentified consecutive patients surviving >5 years after initial GBM resection. Their prospectivelyrncollected demographics, clinical, imaging, and treatment data were retrospectively reviewed andrnanalyzed (under an IRB-approved protocol) from 6/1/1993 to 5/31/2010 (to allow for 5-yearsrnsurvival). EOR was measured volumetrically using pre- and post-op MRI’s. Among 701 newlyrndiagnosed GBM patients, 72 patients (10%) survived ≥5 years; the cohort’s overall median survivalrnwas 13.6 months. Four factors correlated significantly with longer survival on both univariate andrnmultivariate analyses: age, KPS, necrosis on the MRI, and EOR. These factors allowedrnclassification of patients into 4 groups whose >5 years survival varied widely. For patients withrn100% resections, >5-years survival is 50% for Group A, 21% for Group B, 13% for Group C, andrn2% for Group D. The corresponding numbers for patients with <100% resection are: 8% (Group A),rn13% (Group B), 1% (Group C), and 1% (Group D). This is the largest series of long-term GBMrnsurvivors (>5 years), emphasizing the importance of patient selection and of maximizing the EOR.